WHO ICTRP trial
Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have…
NL-OMON50106 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON50106 |
|---|---|
| Public title | Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab |
| Scientific title | Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab - BMS CA209-8TT: Pan tumor Nivolumab Rollover Study |
| Primary sponsor | Bristol-Myers Squibb |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea (the Republic… |
| Conditions | Cancer Pan Tumor;10027655;Cancer;Pan Tumor |
| Interventions | nivolumab at 480 mg IV every 4 weeks or 240 mg IV every 2 weeks per Investigator*s choice ;Cancer;Long term follow-up;Nivolumab;Rollover |
| Registration date | May 18, 2020 |
| Target size | 10 |
| Secondary IDs | 2018-004362-34;NCT03899155;NL72788.078.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: